WO2011012240A3 - Lipopeptide zur therapie und prophylaxe allergischer erkrankungen - Google Patents

Lipopeptide zur therapie und prophylaxe allergischer erkrankungen Download PDF

Info

Publication number
WO2011012240A3
WO2011012240A3 PCT/EP2010/004418 EP2010004418W WO2011012240A3 WO 2011012240 A3 WO2011012240 A3 WO 2011012240A3 EP 2010004418 W EP2010004418 W EP 2010004418W WO 2011012240 A3 WO2011012240 A3 WO 2011012240A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipopeptides
immune system
prophylaxis
therapy
verified
Prior art date
Application number
PCT/EP2010/004418
Other languages
English (en)
French (fr)
Other versions
WO2011012240A2 (de
Inventor
Karl-Heinz Wiesmüller
Söhnke VOSS
Albrecht Bufe
Marcus Peters
Original Assignee
Emc Microcollections Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emc Microcollections Gmbh filed Critical Emc Microcollections Gmbh
Publication of WO2011012240A2 publication Critical patent/WO2011012240A2/de
Publication of WO2011012240A3 publication Critical patent/WO2011012240A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft neue, von einem Sporen-Keimungs-Protein der Spezies Bacillus cereus abgeleitete Lipopeptide, Verfahren zur Herstellung von synthetischen Analoga, die Nutzung ihrer immunstimulatorischen Wirkung zum Zweck der Reifung des Immunsystems und darauf aufbauend deren Verwendung als Wirkstoffe zur Therapie und Prophylaxe zahlreicher allergischer Erkrankungen bei Mensch und Tier, vorzugsweise von allergischem Asthma, sowie Formulierungen von entsprechenden pharmazeutischen Mitteln. Die beschriebenen Lipopeptide tragen durch die Aktivierung der TLR-Rezeptoren 1, 2 und 6 zur Reifung des angeborenen Immunsystems und damit zur Senkung des Allergierisikos bei. Im Tiermodell konnte eine deutliche Reduzierung der Empfindlichkeit gegenüber allergenen Substanzen bei gleichzeitig guter Verträglichkeit nachgewiesen werden. Erstmals wird eine TLR-1, -2, -6 vermittelte Stimulation des angeborenen Immunsystems durch Lipopeptide aus Bakterien-Sporen sowie durch synthetische Analoga derselben auf molekularer Ebene nachgewiesen (Formula (A)).
PCT/EP2010/004418 2009-07-25 2010-07-20 Lipopeptide zur therapie und prophylaxe allergischer erkrankungen WO2011012240A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009034779.8 2009-07-25
DE102009034779A DE102009034779A1 (de) 2009-07-25 2009-07-25 Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen

Publications (2)

Publication Number Publication Date
WO2011012240A2 WO2011012240A2 (de) 2011-02-03
WO2011012240A3 true WO2011012240A3 (de) 2011-09-29

Family

ID=43402447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/004418 WO2011012240A2 (de) 2009-07-25 2010-07-20 Lipopeptide zur therapie und prophylaxe allergischer erkrankungen

Country Status (2)

Country Link
DE (1) DE102009034779A1 (de)
WO (1) WO2011012240A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
DE102016005550B4 (de) * 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
CN114539356B (zh) * 2022-02-21 2023-06-09 中国人民解放军陆军军医大学 一种脂肽及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1387167A1 (de) * 2002-07-24 2004-02-04 Centre National De La Recherche Scientifique (Cnrs) Verfahren um biologische aktive Verbindungen zu identifizieren, die anti-asthmatische, anti-allergische und/oder immunosuppressive Eigenschaften haben
WO2004108145A1 (en) * 2003-06-04 2004-12-16 Gesellschaft für Biotechnologische Forschung mbH Therapeutical composition containing dentritic cells and use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
DE3546150A1 (de) 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
MX9301789A (es) 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
WO1996022067A2 (en) 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
DE19652586A1 (de) 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
DE19822820A1 (de) 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
DE19963840A1 (de) 1999-12-30 2001-09-13 Erika Von Mutius Zusammensetzung zum Vorbeugen und Behandeln von allergischen Erkrankungen
US20030190322A1 (en) 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
DE10048840A1 (de) 2000-10-02 2002-04-11 Biotechnolog Forschung Gmbh Verwendung von Lipopeptiden oder Lipoproteinen zur Behandlung von Lungeninfektionen und -tumoren
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
CA2480196C (en) 2002-04-04 2015-05-12 Gbf Gesellschaft Fuer Biotechnologische Forschung Mbh Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
JP4619121B2 (ja) 2002-08-12 2011-01-26 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｔヘルパーエピトープおよび細胞傷害性ｔリンパ球（ｃｔｌ）エピトープを含む新規な免疫原性リポペプチド
AU2003250586B2 (en) 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
US20040259790A1 (en) 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
RU2351362C2 (ru) 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
GB0308988D0 (en) 2003-04-17 2003-05-28 Univ Singapore Molecule
DE602004031017D1 (de) 2003-07-10 2011-02-24 Cytos Biotechnology Ag Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
KR101126030B1 (ko) 2003-07-15 2012-03-19 이데라 파마슈티칼즈, 인코포레이티드 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
WO2005039504A2 (en) 2003-10-24 2005-05-06 Eisai Co., Ltd. Compounds and methods for treating toll-like receptor 2-related diseases and conditions
EP1550458A1 (de) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergisitische liposomale Adjuvantien
EP1547581A1 (de) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomaler Impstoff für die Behandlung von menschlichen hematologischen mlignen Erkrankungen
KR20060114011A (ko) 2004-01-16 2006-11-03 씨바이오 리미티드 Ｔｏｌｌ-유사 수용체 유도성 사이토킨 및 케모킨 분비의샤페로닌 10 조절
EP1755635A4 (de) 2004-05-27 2011-04-06 Novozymes Biopharma Au Ltd Behandlung von entzündlicher atemwegserkrankung
DE502004008649D1 (de) 2004-09-18 2009-01-22 Protectimmun Gmbh Stallstaub-Extrakt zum Schutz vor Allergien
GB0503509D0 (en) 2005-02-19 2005-03-30 New Royal Holloway & Bedford An improved delivery agent
EP2007421A2 (de) 2005-03-04 2008-12-31 Dynavax Technologies Corporation Impfstoffe enthaltend oligonukleotide mit immunstimulierenden sequenzen (iss), wobei die iss mit antigenen konjugiert und mittels pufferbedingungen und weiteren grundstoffen stabilisiert sind
EA013016B1 (ru) 2005-03-31 2010-02-26 Лейден Юниверсити Медикал Сентер Способы и средства диагностики, профилактики и лечения инфекций mycobacterium и заболевания туберкулезом
CN104278037B (zh) 2005-10-12 2020-09-15 艾德拉药物股份有限公司 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
WO2007078879A2 (en) 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
CA2674269C (en) 2006-01-03 2018-06-12 University Of Georgia Research Foundation, Inc. Three component glycolipopeptides
WO2007098371A2 (en) 2006-02-16 2007-08-30 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
EP2476432B1 (de) 2006-03-07 2015-08-19 Vaxinnate Corporation Zusammensetzungen mit Hämagglutinin, Verfahren zu ihrer Herstellung und Verfahren zu ihrer Verwendung
WO2007118901A2 (en) 2006-04-18 2007-10-25 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Tracheal cytotoxin (tct) and related compounds for suppressing immune responses
JP2010502766A (ja) 2006-06-16 2010-01-28 フロリダ アトランティック ユニヴァーシティ アジュバントとしてのキチン微粒子
EP2046954A2 (de) 2006-07-31 2009-04-15 Curevac GmbH Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
US20080241139A1 (en) 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
JP5714818B2 (ja) 2006-11-09 2015-05-07 ダイナバックス テクノロジーズ コーポレイション 免疫刺激性オリゴヌクレオチドを使用する長期疾患修飾
WO2008059307A2 (en) 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
KR100960567B1 (ko) 2006-11-21 2010-06-03 삼성전자주식회사 무선통신 시스템에서 저복잡도 단말을 지원하기 위한 하이브리드 듀플렉스 장치 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1387167A1 (de) * 2002-07-24 2004-02-04 Centre National De La Recherche Scientifique (Cnrs) Verfahren um biologische aktive Verbindungen zu identifizieren, die anti-asthmatische, anti-allergische und/oder immunosuppressive Eigenschaften haben
WO2004108145A1 (en) * 2003-06-04 2004-12-16 Gesellschaft für Biotechnologische Forschung mbH Therapeutical composition containing dentritic cells and use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
G. VELASCO: "Toll-Like Receptor 4 or 2 Agonists Decrease Allergic Inflammation", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 32, no. 3, 2 December 2004 (2004-12-02), pages 218 - 224, XP055003605, ISSN: 1044-1549, DOI: 10.1165/rcmb.2003-0435OC *
KAY VOGEL: "Microbial spores from farming environments and their role in allergy protection", 1 January 2008 (2008-01-01), Lübeck, Germany, pages 1 - 175, XP055003493, Retrieved from the Internet <URL:http://d-nb.info/99271270X/34> [retrieved on 20110725] *
P. L. PELCZAR ET AL: "Role of GerD in Germination of Bacillus subtilis Spores", JOURNAL OF BACTERIOLOGY, vol. 189, no. 3, 22 November 2006 (2006-11-22), pages 1090 - 1098, XP055003645, ISSN: 0021-9193, DOI: 10.1128/JB.01606-06 *
SPOHN R ET AL: "Synthetic lipopeptide adjuvants and Toll-like receptor 2-structure-activity relationships", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 19, 23 June 2004 (2004-06-23), pages 2494 - 2499, XP004515469, ISSN: 0264-410X, DOI: DOI:10.1016/J.VACCINE.2003.11.074 *
UTE BUWITT-BECKMANN ET AL: "Lipopeptide structure determines TLR2 dependent cell activation level", FEBS JOURNAL, vol. 272, no. 24, 1 December 2005 (2005-12-01), pages 6354 - 6364, XP055003615, ISSN: 1742-464X, DOI: 10.1111/j.1742-4658.2005.05029.x *
VOGEL K ET AL: "Animal shed Bacillus licheniformis spores possess allergy-protective as well as inflammatory properties", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 122, no. 2, 1 August 2008 (2008-08-01), pages 307 - 312.E8, XP023518339, ISSN: 0091-6749, [retrieved on 20080625], DOI: DOI:10.1016/J.JACI.2008.05.016 *

Also Published As

Publication number Publication date
DE102009034779A1 (de) 2011-02-03
WO2011012240A2 (de) 2011-02-03

Similar Documents

Publication Publication Date Title
ATE453642T1 (de) Substituierte phenylaminopyrimidine
SG10201909093XA (en) Mixed allergen compositions and methods for using the same
CY1118934T1 (el) Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
AU2007257423A8 (en) Purine analogs
IN2014DN10391A (de)
WO2013070798A3 (en) Food protein ingredient and methods for producing
MX2012008786A (es) Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbut irato (hmb) de calcio y proteina soluble.
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
MY159208A (en) A novel formulation of indomethacin
NZ596366A (en) Enhanced immune response in avian species
UA112542C2 (uk) Синергетична гербіцидна композиція, що містить пеноксулам і піроксулам
WO2007098964A3 (en) Pyrrazole derivatives as sigma receptors antagonists
EP4349360A3 (de) Peptid mit faltenverbessernder wirkung und verwendungen davon
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
MY185597A (en) Vegetarian protein a preparation and methods thereof
ATE452120T1 (de) Fettsäure-benzenediol-derivate sowie herstellungs-und verwendungsverfahren dafür
WO2011012240A3 (de) Lipopeptide zur therapie und prophylaxe allergischer erkrankungen
WO2009053628A3 (fr) Nouveaux composes, préparation et utilisations
AU2011343331A8 (en) Compositions based on clay and bee pollen, method for preparing same, and nutritional and therapeutic uses thereof
NZ715430A (en) Mammalian milk osteopontin for enhancing immune responsiveness
DE502005008925D1 (de) Substituierte nonadepsipeptide
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
ATE524488T1 (de) Lysobactinamide
WO2007138382A3 (en) Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10747810

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10747810

Country of ref document: EP

Kind code of ref document: A2